|Day's range||8.45 - 8.45|
After market close today, Bionano issued a press release announcing its financial results for the first quarter of 2023. Such forward-looking statements are based upon current expectations, and there can be no assurances that the results contemplated in these statements will be realized.
Bionano Genomics, Inc. (BNGO) delivered earnings and revenue surprises of -33.33% and 1.72%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Illumina (NASDAQ: ILMN) and Bionano Genomics (NASDAQ: BNGO) might both make gene sequencing devices, but as investments the two couldn't be more different. Whereas Bionano is a new entrant to the market and still has a lot to prove to its investors as well as the scientific community, Illumina is the top dog that's fighting to maintain its position. Bulls argue that Illumina is the better gene sequencing stock because in some sequencing markets, it's basically the only option in town, particularly in the all-important market for next generation sequencers (NGS).
Unfortunately for some shareholders, the Bionano Genomics, Inc. ( NASDAQ:BNGO ) share price has dived 37% in the last...
Shares of life sciences company Bionano Genomics (NASDAQ: BNGO) were up nearly 14% late Monday afternoon after the genomic testing equipment maker announced preliminary first-quarter numbers. The company, which manufactures the Saphyr optical genome mapping system, said it has 259 of its systems installed, an increase of 47% over the same period last year. The point of the Saphyr is it helps laboratories more efficiently find aberrations in genes that could cause medical disorders.
Some Bionano Genomics, Inc. ( NASDAQ:BNGO ) shareholders are probably rather concerned to see the share price fall 59...
These fast-paced stocks are on the cutting edge of innovation, and select Wall Street analysts and pundits expect them to skyrocket.
Bionano Genomics (NASDAQ: BNGO) appears to be in just that place -- at the start of its growth journey -- and it could be a great way to give your portfolio some additional upside potential. Bionano's claim to fame is its laboratory analyzer device for optical genome mapping, which it calls the Saphyr.
Image source: The Motley Fool. Bionano Genomics (NASDAQ: BNGO)Q4 2022 Earnings CallMar 09, 2023, 4:30 p.m. ETContents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: OperatorGood day and welcome to the Bionano fourth-quarter and full-year 2022 earnings conference call.
Bionano Genomics, Inc. (BNGO) delivered earnings and revenue surprises of -44.44% and 0.32%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
In that vein, Bionano Genomics (NASDAQ: BNGO) might be a stock you should consider now. The biggest reason to invest in Bionano Genomics today is that it's bringing in revenue like crazy, and its growth story is just getting started. The company develops and sells a piece of highly specialized genomic mapping hardware dubbed the Saphyr that biomedical researchers use to investigate chromosomal abnormalities called structural variations.
One thing we could say about the analysts on Bionano Genomics, Inc. ( NASDAQ:BNGO ) - they aren't optimistic, having...
With the stock falling 37.8% over the last 12 months, shareholders of Bionano Genomics (NASDAQ: BNGO) are bound to be getting a bit frustrated. The genome mapping device manufacturer's fortunes haven't done anything but improve in recent memory, but the market's reception to its successes continues to be fairly cool.
ChromaDex (CDXC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Bionano Genomics, Inc. (BNGO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Wall Street analysts aren't always right with their predictions about stocks, but they typically have a strong argument for why they think a given outcome is going to happen. On that note, let's evaluate a couple of growth stocks that Wall Street has high hopes for to see if they might be a good fit for your portfolio. When it comes to businesses making medical aesthetics treatments that are alternatives to plastic surgeries and face lifts, InMode (NASDAQ: INMD) is a leader.
Here is how Bionano Genomics, Inc. (BNGO) and Amarin (AMRN) have performed compared to their sector so far this year.
After a blistering start to the year, small-cap biotech stocks made a U-turn in the second week of February. Speaking to this point, shares of the optical genome mapping company Bionano Genomics (NASDAQ: BNGO), the next-generation DNA sequencing company Pacific Biosciences of California (NASDAQ: PACB), and the genomics medicine company Sangamo Therapeutics (NASDAQ: SGMO) all tumbled by double digits through the first four days of trading this week, according to data provided by S&P Global Market Intelligence. Prior to this downturn, Bionano Genomics, Pacific Biosciences of California, and Sangamo Therapeutics were all up by double digits for the year.
Here is how Bionano Genomics, Inc. (BNGO) and Aziyo Biologics, Inc. (AZYO) have performed compared to their sector so far this year.
When the curtain closed on 2022, the ageless Dow Jones Industrial Average, widely followed S&P 500, and growth-dependent Nasdaq Composite, respectively finished lower by 9%, 19%, and 33%. It was, collectively, the worst performance for Wall Street in 14 years. This is why most analyst price targets point to upside in equities.
Making specialized scientific instruments requires a lot of time spent on research and development (R&D). Enter Bionano Genomics (NASDAQ: BNGO), a genomics hardware company whose product, the Saphyr optical genome mapping device, is the only technology that can analyze the structural variations of chromosomes at both high efficiency and low cost.
The first fast-paced company with serious upside is hydrogen fuel-cell solution provider Plug Power (NASDAQ: PLUG). According to analyst Amit Dayal of H.C. Wainwright, Plug Power can reach $78. For those of you keeping score at home, this would work out to a near-quintupling in the company's share price in 2023.
Bionano Genomics, Inc. (BNGO) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
Bionano Genomics ( NASDAQ:BNGO ) Third Quarter 2022 Results Key Financial Results Revenue: US$7.22m (up 55% from 3Q...
Penny stocks, defined as equities that trade at under $5 per share, have a bad reputation within many investing circles. Scores of promising early-stage companies have seen their share prices tumble into penny stock territory this year. Which of these newly minted penny stocks offer the most compelling risk-to-reward ratios?